$Theravance Biopharma (TBPH.US)$Revenue has increased from 1...

$Theravance Biopharma(TBPH.US)$Revenue has increased from 15.39 million to 73.41 million over the past 5 years, then declined to 55.31 million, while operating profit has been steadily losing for 5 years, basically at a loss level of 250 million, and net profit is about the same. Revenue shrank in the first three quarters of 2022, and losses also narrowed. The profit from the cessation of operations in Q3 reached 900 million, bringing the profit of the first three quarters to 880 million.